Results 141 to 150 of about 133,054 (344)

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang, Robert A. Hauser, Lorraine V. Kalia, Bonnie Hersh, Zdenek Berger, Roy Llorens Arenas, Coro Paisan‐Ruiz, Kyle Fraser, Danna Jennings, Jillian H. Kluss, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, J. Timothy Greenamyre   +12 more
wiley   +1 more source

Anatomical and functional organization of the human substantia nigra and its connections [PDF]

, 2017
Yu Zhang, Kevin Larcher, Bratislav Mišić, Alain Dagher   +3 more
openalex   +1 more source

An Unusual Motor OFF in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Shreyashi Jha, Mandar S. Jog
wiley   +1 more source

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta‐Analysis

Movement Disorders, EarlyView.
Abstract Background The activation of the NOD‐, LRR‐ and pyrin domain‐containing protein 3 (NLRP3) inflammasome and associated immune dysregulation is one of the key pathological processes preceding and accompanying α‐synuclein pathology, neuronal damage, and cell death in Parkinson's disease (PD).
Alina‐Măriuca Marinescu, Venissa Machado, Gennaro Pagano, Nicoletta Milani Muelhardt, Thomas Kustermann, Eva Zsuzsanna Mracsko, Kathrin Brockmann, Nima Shariati, Judith Anzures‐Cabrera, Bastian Zinnhardt   +9 more
wiley   +1 more source

Additional file 2 of Reduced complement of dopaminergic neurons in the substantia nigra pars compacta of mice with a constitutive “low footprint” genetic knockout of alpha-synuclein

, 2020
Valeria Goloborshcheva, Kirill Chaprov, Е. В. Тетерина, Ruslan K. Ovchinnikov, Vladimir L. Buchman   +4 more
openalex   +1 more source

A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra\n Pars Compacta in Parkinson's Disease [PDF]

, 2020
Vignayanandam Ravindernath Muddapu, Karthik Vijayakumar, Keerthiga Ramakrishnan, V. Srinivasa Chakravarthy   +3 more
openalex   +1 more source

Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research

Movement Disorders Clinical Practice, EarlyView.
Alberto J. Espay, Andrew J. Lees
wiley   +1 more source

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

Substantia Nigra [PDF]

, 2020
openaire   +1 more source

Nuclear Alpha‐Synuclein: Mechanisms and Implications for Synucleinopathies

Movement Disorders, EarlyView.
Abstract Alpha‐synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson's disease (PD) and related synucleinopathies. Recent advances reveal that aSyn dynamically localizes to neuronal nuclei in both health and disease ...
Tiago Fleming Outeiro, David J. Koss
wiley   +1 more source